PDF factsheet
      Z

phosphodiesterase III inhibitors in heart failure for all type of patients, clinical trials results

Amrinone versus placebo
AMTG, 1985
Amrinone <600mg/day
versus
placebo
patients with heart failure NYHA III/IVdouble blind
Follow-up duration: 3 months
Enoximone versus placebo
Cowley, 1994
Enoximone 300mg/d
versus
placebo
NYHA III,IVdouble blind
Follow-up duration: 12 months
enoximone versus placebo
EMOTE, 2007
enoximone
versus
placebo
patients with ultra-advanced heart failure requiring IV inotropic therapydouble blind
Follow-up duration: 26 weeks
US
Enoximone versus placebo
EMTG, 1990
Enoximone <450 mg/d
versus
placebo
NYHA II, IIIdouble blind
Follow-up duration: 4 months
ESG, 2000
Enoximone 75-150 mg/d
versus
placebo
NYHA II, IIIdouble blind
Follow-up duration: 3 months
enoximone versus placebo
ESSENTIAL (I and II), 2009
NCT00051285
enoximone titrated to 50 mg three times daily
versus
placebo
Patients with New York Heart Association class III–IV HF symptoms, left ventricular ejection fraction 30%, and one hospitalization or two ambulatory visits for worsening HF in the previous yeardouble blind
Follow-up duration: 16.6 mo (median)
Europe and North andSouth America
Enoximone versus placebo
Lardoux, 1987
Enoximone 150, 300mg/d
versus
placebo
NYHA NAdouble blind
Follow-up duration: 3 months
WESG, 1991
Enoximone 150, 300 mg/d
versus
placebo
NYHA II, IIIdouble blind
Follow-up duration: 3 months
Flosequinan versus placebo
REFLECT II, 1991
Flosequinan 100, 150 mg/d
versus
NYHA II-IVdouble blind
Follow-up duration: 3 months
Cowley, 1993
Flosequinan 125mg/d
versus
placebo
NYHA II, IIIdouble blind
Follow-up duration: 4 months
FACET, 1993
Flosequinan 100 and 150 mg/d
versus
placebo
NYHA II, IIIdouble blind
Follow-up duration: 4 months
REFLECT, 1993
Flosequinan 100mg/d
versus
placebo
NYHA II,IIIdouble blind
Follow-up duration: 3 months
ibopamine versus placebo
PRIME II, 1997
oral ibopamine 100 mg three times daily
versus
placebo
patients with heart failure NYHA III-IVdouble blind
Follow-up duration: mean 11.4 months
Imazodan versus placebo
IRG, 1991
Imazodan 4,10, 20 mg/d
versus
placebo
NYHA III,IVdouble blind
Follow-up duration: 3 months
Indolidan versus placebo
Dies, 1989
Indolidan dose NA
versus
placebo
NYHA II,IIIdouble blind
Follow-up duration: 3 months
Milrinone versus placebo
MMTG, 1989
Milrinone <40mg/d
versus
placebo
NYHA II-IVdouble blind
Follow-up duration: 3 months
PROMISE, 1991
Milrinone 40mg/d
versus
placebo
NYHA III,IVdouble blind
Follow-up duration: 20 months
Pimobendan versus placebo
Bergler-Klein, 1992
Pimobendan 10mg/day
versus
placebo
NYHA II, IIIdouble blind
Follow-up duration: 6 months
PMRG, 1992
Pimobendan 2.5, 5, 10 mg/d
versus
placebo
NYHA III,IVdouble blind
Follow-up duration: 3 months
EPOCH, 2002
Pimobendan 2.5 to 5mg/d
versus
placebo
NYHA II,IIIdouble blind
Follow-up duration: 12 months
PICO, 1996
Pimobendan 2.5, 5 mg/d
versus
placebo
NYHA II, IIIdouble blind
Follow-up duration: 6 months
Vesnarinone versus placebo
OPC-8212 MRG, 1990
Vesnarinone 60mg/d
versus
placebo
NYHA II-IVdouble blind
Follow-up duration: 3 months
VEST, 1998
Vesnarinone 30, 60mg/d
versus
placebo
NYHA III,IVdouble blind
Follow-up duration: 9 months
VSG, 1993
Vesnarinone 60mg/d
versus
placebo
NYHA II-IVdouble blind
Follow-up duration: 6 months

  Options


in first

in second

  Filter